HC Wainwright Weighs in on Disc Medicine FY2030 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at HC Wainwright issued their FY2030 earnings per share estimates for Disc Medicine in a research note issued on Monday, January 26th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings per share of $8.37 for the year. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

A number of other equities research analysts have also issued reports on the company. Truist Financial increased their price target on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, November 10th. National Bankshares set a $153.00 price objective on Disc Medicine in a research note on Friday, October 17th. UBS Group reissued an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Cantor Fitzgerald boosted their target price on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a research report on Friday, October 17th. Finally, Wells Fargo & Company increased their price objective on shares of Disc Medicine from $91.00 to $109.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $119.45.

Disc Medicine Price Performance

Shares of IRON opened at $77.54 on Tuesday. The firm has a 50-day simple moving average of $84.14 and a two-hundred day simple moving average of $73.56. Disc Medicine has a 1-year low of $30.82 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The stock has a market cap of $2.93 billion, a PE ratio of -14.49 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29).

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in Disc Medicine by 11.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock worth $44,678,000 after purchasing an additional 84,278 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Disc Medicine during the 3rd quarter worth about $689,000. Sio Capital Management LLC grew its position in Disc Medicine by 287.4% in the 2nd quarter. Sio Capital Management LLC now owns 284,787 shares of the company’s stock valued at $15,082,000 after purchasing an additional 211,276 shares during the period. Geode Capital Management LLC grew its holdings in shares of Disc Medicine by 4.7% during the second quarter. Geode Capital Management LLC now owns 598,589 shares of the company’s stock valued at $31,705,000 after buying an additional 26,605 shares during the last quarter. Finally, Bollard Group LLC bought a new stake in Disc Medicine during the 2nd quarter worth approximately $1,622,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider William Jacob Savage sold 13,093 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the completion of the sale, the insider directly owned 75,702 shares of the company’s stock, valued at $6,905,536.44. This trade represents a 14.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John D. Quisel sold 40,000 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $93.05, for a total transaction of $3,722,000.00. Following the completion of the sale, the chief executive officer owned 171,828 shares of the company’s stock, valued at $15,988,595.40. This represents a 18.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 275,470 shares of company stock worth $24,966,170. Company insiders own 3.64% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.